The Global Rapid Microbiology Testing Market in terms of revenue was estimated to be worth $4.2 billion in 2021 and is poised to reach $6.7 billion by 2026, growing at a CAGR of 9.4% from 2021 to 2026.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=31548521
Market Drivers
- Increasing incidence of infectious diseases and cancer
- Technological advancements in rapid microbiology testing
- Increased funding for R&D
- Increased focus on the early detection of infectious diseases
Market Opportunities
- Growth opportunities in emerging countries
- Expansion of online platforms for rapid testing
- Emergence of new technologies
Market Challenges
- Operational barriers
- Low Diagnostic Accuracy
Request 10% Customization:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=31548521
Rapid Microbiology Testing Market Segmentation:
By Product
- Instruments
- Reagents and Kits
By Method
- Growth-Based Rapid Microbiology Testing
- Cellular component-Based Rapid Microbiology Testing
- Nucleic Acid-Based Rapid Microbiology Testing
- Viability-Based Rapid Microbiology Testing
By Applications
- Clinical Disease Diagnostics
- Food & Beverage testing
- Pharmaceutical & Biological Drug Testing
- Environmental Testing
- Cosmetics and Personal Care Products Testing
- Research Applications
- Other Applications
North America is the largest regional market for PCR Systems
The global rapid microbiology testing market is segmented into five major regions North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the global rapid microbiology testing market. The North American rapid microbiology testing market’s growth can be attributed to the increased government initiatives for healthcare development, increased awareness on the early detection of infectious disease and increased incidence of infectious disease and cancer.
Recent Developments
- In October 2020, Merck KGAA (Germany) collaborated with Mammoth Biosciences (US) for the development, scale up and commercial production of CRISPR- based SARS-COV-2 diagnostic test.
- In September 2020, Bruker Corporation (US) has an acquisition with Canopy Bioscience LLC ( US) which enhanced bruker’s offerings in targeted multi-omics and fluorescence-based imaging technique.
- In July 2020, Biomérieux SA (France) launched Biofire mycoplasma test for the detection of mycoplasma in biopharmaceutical products.
Key Players:
Abbott Laboratories, Inc. (US), Becton, Dickinson and Company (US), bioMérieux SA (France), Bruker Corporation (US), Charles River Laboratories International, Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), NEOGEN Corporation (US), Quidel Corporation (US), Sartorius AG (Germany), Thermo Fisher Scientific, Inc. (US)
Report Link: ( Rapid Microbiology Testing Market )
